Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Rein Therapeutics (RNTX) Assets Average (2017 - 2025)

Rein Therapeutics (RNTX) has disclosed Assets Average for 9 consecutive years, with $55.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Assets Average fell 47.95% to $55.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $55.6 million, a 47.95% decrease, with the full-year FY2024 number at $84.1 million, up 31.39% from a year prior.
  • Assets Average was $55.6 million for Q3 2025 at Rein Therapeutics, down from $57.6 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $106.8 million in Q3 2024 to a low of $13.4 million in Q3 2023.
  • A 5-year average of $54.0 million and a median of $55.6 million in 2025 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: tumbled 57.92% in 2023, then skyrocketed 696.69% in 2024.
  • Rein Therapeutics' Assets Average stood at $51.6 million in 2021, then tumbled by 52.31% to $24.6 million in 2022, then surged by 141.33% to $59.4 million in 2023, then soared by 40.04% to $83.2 million in 2024, then crashed by 33.18% to $55.6 million in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Assets Average are $55.6 million (Q3 2025), $57.6 million (Q2 2025), and $59.9 million (Q1 2025).